Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64


Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.

Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA.

Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):371-4. doi: 10.1097/PAI.0b013e3181d50bd5.


Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.

Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B.

Int J Gynecol Pathol. 2012 Jan;31(1):48-56. doi: 10.1097/PGP.0b013e3182230d00.


A robust immunohistochemical assay for detecting PTEN expression in human tumors.

Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, Stone S.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83. doi: 10.1097/PAI.0b013e3181f1da13.


Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.

Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, Mao M, Chung HC, Zheng G.

Exp Mol Pathol. 2016 Apr;100(2):287-93. doi: 10.1016/j.yexmp.2015.11.027. Epub 2015 Nov 25.


Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry.

Schläfli AM, Berezowska S, Adams O, Langer R, Tschan MP.

Eur J Histochem. 2015 May 5;59(2):2481. doi: 10.4081/ejh.2015.2481.


PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.

Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244. Epub 2011 Aug 30.


PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.

Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N.

Br J Cancer. 2006 Jan 30;94(2):247-52.


Evaluation of methods for preserving PTEN antigenicity in stored paraffin sections.

Gelb AB, Freeman VA, Astrow SH.

Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):569-73. doi: 10.1097/PAI.0b013e318217a3d3.


PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.


Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.

Park S, Wang HY, Kim S, Ahn S, Lee D, Cho Y, Park KH, Jung D, Kim SI, Lee H.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6752-9. eCollection 2014.


Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.

Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A.

Clin Cancer Res. 2010 Aug 15;16(16):4226-35. doi: 10.1158/1078-0432.CCR-10-0410. Epub 2010 Jul 27.


Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9. Epub 2007 Apr 23.


Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.


EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.

Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681. Epub 2009 Feb 2.


Brief fixation does not affect assessment of hormone receptor expression in invasive breast carcinoma biopsies: paving the road for same-day tissue diagnostics.

Kalkman S, Barentsz MW, Witkamp AJ, van der Wall E, Verkooijen HM, van Diest PJ.

Am J Surg Pathol. 2014 Aug;38(8):1071-8. doi: 10.1097/PAS.0000000000000207.


Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy.

Krüger JM, Thomas M, Korn R, Dietmann G, Rutz C, Brockhoff G, Specht K, Hasmann M, Feuerhake F.

Am J Pathol. 2013 Aug;183(2):336-43. doi: 10.1016/j.ajpath.2013.04.010. Epub 2013 May 29.


A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.

Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S.

J Immunol Methods. 2005 Apr;299(1-2):139-51. Epub 2005 Apr 1.


Preparation of formalin-fixed paraffin-embedded tissue for immunohistochemistry.

Canene-Adams K.

Methods Enzymol. 2013;533:225-33. doi: 10.1016/B978-0-12-420067-8.00015-5.


Supplemental Content

Support Center